Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites
US4574079A · kind A · utility
Inventors
Key dates
| Filing date | May 27, 1983 |
| Grant date | Mar 4, 1986 |
| Priority date | — |
| Expiry date | May 27, 2003 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2123/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Radiolabeled angiotensin converting enzyme inhibitors having the general formula: ##STR1## wherein X is a radiolabeling substituent, preferably a radiolabeling halogen substituent such as .sup.123 I, .sup.125 I, .sup.131 I, .sup.75 Br or .sup.77 Br, PA0 Y is hydroxy, alkoxy containing from 1 to 6 carbon atoms, phenoxy, benzyloxy, or amino, PA0 R.sub.1 is hydrogen or methyl, PA0 R.sub.2 is hydrogen, an ester moiety hydrolyzable under mammalian in vivo conditions, such as alkyl of 1 or 2 carbon atoms, phenyl or benzyl, or an ionically bonded anion of a physiologically acceptable non-toxic salt, and PA0 m is an integer of from 1 to 6, are useful as in vivo radioimaging compounds for mammalian sites.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.